β-Secretases, Alzheimer's Disease, and Down Syndrome
Individuals with Down Syndrome (DS), or trisomy 21, develop Alzheimer's disease (AD) pathology by approximately 40 years of age. Chromosome 21 harbors several genes implicated in AD, including the amyloid precursor protein and one homologue of the β-site APP cleaving enzyme, BACE2. Processing o...
Main Authors: | Webb, Robin L., Murphy, M. Paul |
---|---|
Format: | Online |
Language: | English |
Published: |
Hindawi Publishing Corporation
2012
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3299320/ |
Similar Items
-
The Alzheimer's disease β-secretase enzyme, BACE1
by: Cole, Sarah L, et al.
Published: (2007) -
The β-secretase enzyme BACE1 as a therapeutic target for Alzheimer's disease
by: Vassar, Robert, et al.
Published: (2011) -
Effects of berberine on β-secretase activity in a rabbit model of Alzheimer's disease
by: Panahi, Negar, et al.
Published: (2013) -
The role and therapeutic targeting of α-, β- and γ-secretase in Alzheimer's disease
by: MacLeod, Ruth, et al.
Published: (2015) -
β-secretase inhibitor; a promising novel therapeutic drug in Alzheimer’s disease
by: Menting, Kelly Willemijn, et al.
Published: (2014)